1
|
Sorce G, Stabile A, Pellegrino F, Mazzone E, Mattei A, Afferi L, Serni S, Minervini A, Roumiguiè M, Malavaud B, Valerio M, Rakauskas A, Marra G, Gontero P, Porpiglia F, Guo H, Zhuang J, Gandaglia G, Montorsi F, Briganti A. The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology. World J Urol 2024; 42:248. [PMID: 38647689 DOI: 10.1007/s00345-024-04963-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Accepted: 03/25/2024] [Indexed: 04/25/2024] Open
Abstract
PURPOSE Although targeted biopsies (TBx) are associated with improved disease assessment, concerns have been raised regarding the risk of prostate cancer (PCa) overgrading due to more accurate biopsy core deployment in the index lesion. METHODS We identified 1672 patients treated with radical prostatectomy (RP) with a positive mpMRI and ISUP ≥ 2 PCa detected via systematic biopsy (SBx) plus TBx. We compared downgrading rates at RP (ISUP 4-5, 3, and 2 at biopsy, to a lower ISUP) for PCa detected via SBx only (group 1), via TBx only (group 2), and eventually for PCa detected with the same ISUP 2-5 at both SBx and TBx (group 3), using multivariable logistic regression models (MVA). RESULTS Overall, 12 vs 14 vs 6% (n = 176 vs 227 vs 96) downgrading rates were recorded in group 1 vs group 2 vs group 3, respectively (p < 0.001). At MVA, group 2 was more likely to be downgraded (OR 1.26, p = 0.04), as compared to group 1. Conversely, group 3 was less likely to be downgraded at RP (OR 0.42, p < 0.001). CONCLUSIONS Downgrading rates are highest when PCa is present in TBx only and, especially when the highest grade PCa is diagnosed by TBx cores only. Conversely, downgrading rates are lowest when PCa is identified with the same ISUP through both SBx and TBx. The presence of clinically significant disease at SBx + TBx may indicate a more reliable assessment of the disease at the time of biopsy potentially reducing the risk of downgrading at final pathology.
Collapse
Affiliation(s)
- G Sorce
- Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy
| | - A Stabile
- Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
- Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
| | - F Pellegrino
- Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy
| | - E Mazzone
- Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy
| | - A Mattei
- Klinik Für Urologie, Luzerner Kantonsspital, Luzerner, Switzerland
| | - L Afferi
- Klinik Für Urologie, Luzerner Kantonsspital, Luzerner, Switzerland
| | - S Serni
- Department of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy
| | - A Minervini
- Department of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy
| | - M Roumiguiè
- Department of Urology and Renal Transplantation, Toulouse University Hospital, Toulouse, France
| | - B Malavaud
- Department of Urology and Renal Transplantation, Toulouse University Hospital, Toulouse, France
| | - M Valerio
- Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - A Rakauskas
- Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - G Marra
- Department of Urology, Città della Salute e della Scienza, University of Turin, Turin, Italy
| | - P Gontero
- Department of Urology, Città della Salute e della Scienza, University of Turin, Turin, Italy
| | - F Porpiglia
- Division of Urology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
| | - H Guo
- Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China
| | - J Zhuang
- Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China
| | - G Gandaglia
- Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy
| | - F Montorsi
- Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy
| | - A Briganti
- Unit of Urology, Division of Oncology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy
| |
Collapse
|
2
|
Brush BL, Lee SYD, Gabrysiak A, Jensen M, Wilson-Powers E, Coombe CM, Paul Chandanabhumma P, Valerio M, Israel BA, Lachance L. A CBPR-Enhanced Delphi Method: The Measurement Approaches to Partnership Success Case Study. Health Educ Behav 2024; 51:212-217. [PMID: 35189738 PMCID: PMC10040148 DOI: 10.1177/10901981221076400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
As part of a 5-year study to develop and validate an instrument for measuring success in long-standing community-based participatory research (CBPR) partnerships, we utilized the Delphi method with a panel of 16 community and academic CBPR experts to assess face and content validity of the instrument's broad concepts of success and measurement items. In addition to incorporating quantitative and qualitative feedback from two online surveys, we included a 2-day face-to-face meeting with the Expert Panel to invite open discussion and diversity of opinion in line with the CBPR principles framing and guiding the study. The face-to-face meeting allowed experts to review the survey data (with maintained anonymity), convey their perspectives, and offer interpretations that were untapped in the online surveys. Using a CBPR approach facilitated a synergistic process that moved above and beyond the consensus achieved in the initial Delphi rounds, to enhance the Delphi technique and the development of items in the instrument.
Collapse
Affiliation(s)
| | | | - Adena Gabrysiak
- University of Michigan School of Public Health, Ann Arbor, MI
| | - Megan Jensen
- University of Michigan School of Public Health, Ann Arbor, MI
| | | | - Chris M. Coombe
- University of Michigan School of Public Health, Ann Arbor, MI
| | | | - Melissa Valerio
- University of Texas Health Science Center School of Public Health, Houston, TX
| | | | - Laurie Lachance
- University of Michigan School of Public Health, Ann Arbor, MI
| |
Collapse
|
3
|
Kang H, Hoang DH, Valerio M, Pathak K, Zhang L, Buettner R, Chen F, Estrella K, Graff W, Li Z, Xie J, Horne D, Kuo YH, Zhang B, Pirrotte P, Nguyen LXT, Marcucci G. OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia. Leukemia 2024; 38:657-662. [PMID: 38233463 PMCID: PMC10912030 DOI: 10.1038/s41375-024-02146-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Revised: 01/06/2024] [Accepted: 01/08/2024] [Indexed: 01/19/2024]
Affiliation(s)
- HyunJun Kang
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA
| | - Dinh Hoa Hoang
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA
| | - Melissa Valerio
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA
| | - Khyatiben Pathak
- Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA
| | - Lianjun Zhang
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA
| | - Ralf Buettner
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA
| | - Fang Chen
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA
| | - Katrina Estrella
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA
| | | | - Zhuo Li
- Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA
| | - Jun Xie
- Department of Molecular Medicine, City of Hope National Medical Center, Duarte, CA, USA
| | - David Horne
- Department of Molecular Medicine, City of Hope National Medical Center, Duarte, CA, USA
| | - Ya-Huei Kuo
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA
| | - Bin Zhang
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA
| | - Patrick Pirrotte
- Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA
| | - Le Xuan Truong Nguyen
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA.
- Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
| | - Guido Marcucci
- Department of Hematologic Malignancies Translational Science, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA.
| |
Collapse
|
4
|
Cobos A, Valerio M, Palomo M, Adán I, Catalán P, Veintimilla C, López-Andújar F, Rincón C, Galar A, Alonso R, Machado M, Gijón P, Aldámiz-Echevarría Lois T, Pérez Latorre L, Diez C, Fanciulli C, Bouza Santiago E, Muñoz P. Demographic, clinical and microbiological characteristics of the first 30 human monkeypox confirmed cases attended in a tertiary hospital in Madrid (Spain), during the May-June 2022 international outbreak. Rev Esp Quimioter 2023; 36:194-200. [PMID: 36651283 PMCID: PMC10066919 DOI: 10.37201/req/112.2022] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The present outbreak of Human Monkeypox (HMPX) that has begun in May 2022 and has spread across all continents in less than two months has qualitative and quantitative characteristics that make it different from the pattern of human disease previously caused by this virus. It has spread with enormous ease, affects almost exclusively adults, behaves as a sexually transmitted disease and focuses on very specific groups and transmission conditions. The high incidence in the city of Madrid in males that have sex with males (MSM) has allowed us to observe and report the experience with the first 30 cases diagnosed in our institution. Patients presented with febrile symptoms, genital and paragenital skin lesions reminiscent of smallpox, but less extensive and severe. The disease may also cause proctitis, pharyngitis and perioral lesions. The PCR test for diagnostic confirmation has been shown to be very sensitive and effective, not only in skin lesions but also in blood and other fluids such as pharyngeal, rectal exudates and blood. A very high proportion of patients with HMPX also have other sexually transmitted diseases that must be actively detected in this context. The spontaneous evolution of our patients has been good and hospitalization has been practically unnecessary. Transmission to non-sexual cohabitants and health personnel has been nonexistent and the lesions have disappeared in less than 30 days without leaving sequelae and no need for specific antiviral treatment.
Collapse
Affiliation(s)
| | - M Valerio
- Maricela Valerio. Professor of School of Medicine, Universidad Complutense de Madrid, Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Stabile A, Gandaglia G, Pellegrino F, Afferi L, Zhuang J, Guo H, Gontero P, Minervini A, Ploussard G, Mazzone E, Valerio M, Cucchiara V, Fossati N, Moschini M, Mattei A, Serni S, Rahota R, Beauval J, Marquis A, Rakauskas A, Van Den Bergh R, Soeterik T, Montorsi F, Briganti A. mpMRI of the prostate in patients carrying a high clinical risk of prostate cancer diagnosis: Is this imaging test necessary for diagnostic purposes in this subset of patients? Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00146-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
6
|
Stabile A, Gandaglia G, Pellegrino F, Mazzone E, Cucchiara V, Fossati N, Moschini M, Mattei A, Afferi L, Serni S, Minervini A, Rahota RG, Ploussard G, Valerio M, Beauval J, Marquis A, Rakauskas A, Gontero P, Guo H, Zhuang J, Van Den Bergh R, Soeterik T, Montorsi F, Briganti A. Integrating index lesion volume to better classify men with indolent prostate cancer among patients with intermediate risk disease. Results from a large, multi-institutional series. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00147-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
7
|
Sorce G, Gandaglia G, Stabile A, Cucchiara V, Mazzone E, Fossati N, Moschini M, Mattei A, Afferi L, Serni S, Minervini A, Rahota RG, Ploussard G, Valerio M, Beavaul J, Marquis A, Rakauskas A, Gontero P, Guo H, Zhuang J, Van Den Bergh R, Soeterik T, Montorsi F, Briganti A. Has the introduction of multiparametric magnetic resonance imaging of the prostate and targeted biopsies led to a risk of overgrading of high risk prostate cancer? Results from a contemporary, large multi-institutional series. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01271-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
8
|
Zattoni F, Pereira L, Zhuang J, Olivier J, Puche-Sanz I, Rajwa P, La Bombarda G, Maggi M, Fuschi A, Veccia A, Ditonno F, Marra G, Valerio M, Kasivisvanathan V, Alessandro A, Dal Moro F, Rivas J, Van Den Bergh R, Gandaglia G, Novara G. Prostate cancer detection rate of repeated biopsy in patients with positive mpMRI and negative initial target and random biopsy. An EAU-YAU Prostate Cancer Working Group multi-institutional study. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00121-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
9
|
Schaer S, Rakauskas A, Valerio M, Roth B. A preliminary assessment of microultrasound performance in detecting clinically significant prostate cancer in the anterior prostate: An inter-reader evaluation. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01016-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
10
|
Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, Muñoz P, Valerio M, Catalán P, Burillo A, Cobo A, Alcamí A, Bouza E. Monkeypox in humans: a new outbreak. Rev Esp Quimioter 2022; 35:509-518. [PMID: 35785957 PMCID: PMC9728594 DOI: 10.37201/req/059.2022] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 07/01/2022] [Indexed: 12/24/2022]
Abstract
Infection caused by Monkeypox Virus (MPVX) has small rodents as its natural reservoir and both monkeys and humans are occasional hosts. The causative agent is an Orthopoxvirus (MPVX) that was isolated in monkeys in 1958 and proved capable of passing to humans in 1970. It remained contained in Africa, causing isolated episodes of infection, until 2003 when an outbreak occurred in the United States following importation of animals from that continent. Since then, anecdotal cases have continued to be reported outside Africa, usually very clearly linked to travelers to those countries, but in May 2022, a broad outbreak of this disease has begun, now affecting several continents, with the emergence of human cases of MPVX (H-MPVX) infection mainly among Men that have Sex with Men (MSM). The disease has an incubation time ranging from 5 to 15 days and is characterized by the presence of pustules, fever, malaise and headache. The presence of significant regional lymphadenopathy is a differential feature with episodes of classical smallpox. Proctitis and pharyngitis, with minimal skin lesions, may be another form of presentation. Diagnosis can be confirmed by PCR testing of lesions or by demonstration of MPVX in other body fluids or tissues, although in the appropriate epidemiologic setting the clinical picture is highly suggestive of the disease. Effective drug treatment has been developed as part of programs to protect against potential bioterrorist agents and smallpox vaccinees are known to have high protection against monkeypox. New vaccines are available, but neither the drugs nor the vaccines are yet freely available on the market. The prognosis of the disease appears, at least in adults in developed countries, to be good, with very low mortality figures and much less aggressive behavior than that described in classical smallpox. Isolation measures, essential for the control of the outbreak, have been published by the health authorities.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - E Bouza
- Servicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain.
| |
Collapse
|
11
|
Martini A, Wever L, Soeterik T, Rakauskas A, Fankhauser C, Grogg J, Checcucci E, Ploussard G, Qiang P, Affentranger A, Marra G, Ettala O, Zattoni F, Falagario U, De Angelis M, Kesch C, Apfelbeck M, Al-Hammouri T, Kretschmer A, Kasivisvanathan V, Preisser F, Olivier J, Radtke J, Carrieri G, Jambor I, Gontero P, Briganti A, Macek P, Chiu P, Hermanns T, Van Den Bergh R, Gandaglia G, Valerio M. Unilateral pelvic lymph node dissection in prostate cancer patients diagnosed in the era of MRI-targeted biopsy: A study that challenges the dogma. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02492-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
12
|
Gandaglia G, Mazzone E, Ploussard G, Marra G, Valerio M, Campi R, Mari A, Minervini A, Serni S, Moschini M, Marquis A, Beauval J, Rakauskas A, Sessa F, van den Bergh R, Rahota R, Soeterik T, Roumiguiè M, Afferi L, Zhuang J, Guo H, Mattei A, Gontero P, Cucchiara V, Stabile A, Fossati N, Montorsi F, Briganti A. Outcomes of prostate cancer patients with seminal vesicle invasion at multiparametric MRI managed with radical prostatectomy. Do all patients really need for a multi-modal approach? EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01240-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
13
|
Quarta L, Stabile A, Mazzone E, Gandaglia G, Longoni M, Ploussard G, Rahota R, Valerio M, Campi R, Mari A, Mattei A, Marra G, Beauval J, Roumiguiè M, Afferi L, Moschini M, Gontero P, van den Bergh R, Zhuang J, Tuo H, Fossati N, Montorsi F, Briganti A. The prognostic value of the number of positive targeted cores in men with positive multiparametric magnetic resonance imaging of the prostate. results from a large, multi-institutional series. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01283-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
14
|
Ghezzi L, Valerio M, Petrini R. Novel Determination of Elemental Mercury in Silicate Rock by Thermal Desorption. ANAL LETT 2022. [DOI: 10.1080/00032719.2022.2125984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Affiliation(s)
- L. Ghezzi
- Dipartimento di Scienze della Terra, University of Pisa, Pisa, Italy
| | - M. Valerio
- Dipartimento di Scienze della Terra, University of Pisa, Pisa, Italy
| | - R. Petrini
- Dipartimento di Scienze della Terra, University of Pisa, Pisa, Italy
| |
Collapse
|
15
|
Garcia-Montero M, Ortiz-Bautista C, Valerio M, Olmedo M, Muñoz P, Zatarain Nicolás E, Fernandez-Cordon C, Fernández-Avilés F. Herpes zoster complicated with aseptic meningitis after cardiac transplantation: Report of two cases and review of the literature. Rev Esp Quimioter 2022; 35:415-417. [PMID: 35818634 PMCID: PMC9333122 DOI: 10.37201/req/033.2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- M Garcia-Montero
- Marta García Montero, Cardiology Department, Hospital General Universitario Gregorio Marañón. Calle Doctor Esquerdo 46, 28007, Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
de la Villa S, Rojas A, Estévez A, Álvarez-Uria A, Valerio M, Machado M, Kestler M, Ramallo VG, Abella HR, Bouza E, Muñoz P. Endocarditis Infecciosa Causada Por Microorganismos Multirresistentes. Cirugía Cardiovascular 2022. [DOI: 10.1016/j.circv.2022.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
17
|
de la Villa S, Rojas A, Álvarez-Uria A, Valerio M, Machado M, Kestler M, Bouza E, Muñoz P. VALIDACIÓN DE DOS SCORES PREDICTORES DE ENDOCARDITIS EN BACTERIEMIA POR S. AUREUS. Cirugía Cardiovascular 2022. [DOI: 10.1016/j.circv.2022.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
18
|
Estévez A, Machado M, Valerio M, Sánchez C, Marín M, Adán I, Bouza E, Hualde AM, Pinilla B, Muñoz P. Endocarditis polimicrobiana, ¿una entidad real? Análisis de nuestra cohorte de endocarditis HGUGM 2008-2020. Cirugía Cardiovascular 2022. [DOI: 10.1016/j.circv.2022.03.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
19
|
Martel P, Rakauskas A, Dagher J, La Rosa S, Meuwly JY, Roth B, Valerio M. The benefit of adopting Microultrasound in the prostate cancer imaging pathway: A lesion-by-lesion analysis: Biopsies prostatiques guidée par micro-échographie, quel bénéfice ? Une analyse lésion par lésion. Prog Urol 2022; 32:6S26-6S32. [PMID: 36719643 DOI: 10.1016/s1166-7087(22)00172-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
INTRODUCTION - Microultrasound (MicroUS) is a novel imaging modality relying on a high-frequency transducer which confers a three-fold improvement in spatial resolution as compared with conventional transrectal ultrasound. We evaluated the diagnostic value of MRI-MicroUS fusion biopsy and determined the additional benefit of employing MicroUS. METHODS - Retrospective analysis of consecutive treatment-naïve men undergoing MRI-MicroUS fusion biopsy between May 2018 and March 2019. Pre-biopsy MRI was systematically reviewed in a dedicated meeting where suspicious lesions PIRADS ≥ 3 were registered and uploaded in the ExactVu MicroUS device. MRI and MicroUS lesions were individually marked in a PIRADS v2 scheme. The biopsy protocol included MRI-MicroUS fusion and MicroUS targeted biopsies; systematic biopsies were performed at clinician's discretion. The diagnostic value was evaluated in terms of detection rate of clinically significant prostate cancer, defined as Gleason pattern ≥ 4 at histology. RESULTS - In all, 148 patients with a median age of 69 years (IQR 63-74) and median PSA density of 0.16 ng/ml/cc (0.10-0.23) were included. Clinically significant cancer was detected in 42.5% (63/148) patients. MRI detected 89 lesions in the peripheral zone; 73% (65/89) were visible on MicroUS. Clinically significant cancer was detected in 46.1% (30/65) MRI and MicroUS visible lesions, and in 4.2% (1/24) lesions only visible on mpMRI. MicroUS additionally identified 35 suspicious lesions non-visible on MRI of which clinically significant cancer was present in 25.7% (9/35). CONCLUSION - Adding MicroUS to the conventional pathway seems to increase the detection rate of clinically significant disease in unselected men undergoing biopsy. © 2022 Elsevier Masson SAS. All rights reserved.
Collapse
Affiliation(s)
- P Martel
- Department of Urology, Lausanne University Hospital, Lausanne, Switzerland
| | - A Rakauskas
- Department of Urology, Lausanne University Hospital, Lausanne, Switzerland
| | - J Dagher
- Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland
| | - S La Rosa
- Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland; Pathology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy
| | - J Y Meuwly
- Department of Radiology, Lausanne University Hospital, Lausanne, Switzerland
| | - B Roth
- Department of Urology, Lausanne University Hospital, Lausanne, Switzerland
| | - M Valerio
- Department of Urology, Lausanne University Hospital, Lausanne, Switzerland.
| |
Collapse
|
20
|
Olmedo M, Kestler M, Valerio M, Padilla B, Rodríguez González C, Chamarro E, Machado M, Álvarez-Uría A, Alcalá L, Muñoz P, Bouza E. Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience. Rev Esp Quimioter 2022; 35:279-283. [PMID: 35279984 PMCID: PMC9134882 DOI: 10.37201/req/120.2021] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 12/15/2021] [Accepted: 01/15/2022] [Indexed: 12/02/2022]
Abstract
OBJECTIVE Following the approval of bezlotoxumab in 2017, studies evaluating its effectiveness in prevention of Clostridioides difficile infection under "real-life" conditions are scarce. METHODS We conducted a retrospective study developed in a large tertiary care hospital describing the use and outcomes of patients with Clostridioides difficile infection (CDI) treated with bezlotoxumab. RESULTS A total of 16 patients were include, all of whom had an episode of CDI with high probability of recurrence and 14 of them had some kind of immunosuppression. Bezlotoxumab was effective in the prevention of CDI recurrence in 11 of the 14 cases in which follow up was possible, without significant side effects. CONCLUSIONS Bezlotoxumab was well tolerated and the incidence of recurrent CDI in a high-risk population for recurrence was only 21.4%.
Collapse
Affiliation(s)
- M Olmedo
- María Olmedo, Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Del Castillo C, Castrodeza J, Blázquez Z, Ortiz-Bautista C, Valerio M, Valero M, Navas P, Villa A, Sousa I, Zatarain E, Martínez-Sellés M, Fernández-Avilés F. Late Cytomegalovirus Primoinfection in a Heart Transplant Recipient After COVID-19 Vaccine. J Heart Lung Transplant 2022. [PMCID: PMC8988561 DOI: 10.1016/j.healun.2022.01.1696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
22
|
Martel P, Rakauskas A, Dagher J, La Rosa S, Meuwly JY, Roth B, Valerio M. WITHDRAWN: The benefit of adopting Microultrasound in the prostate cancer imaging pathway : A lesion-by-lesion analysis. Prog Urol 2022:S1166-7087(22)00066-5. [PMID: 35292179 DOI: 10.1016/j.purol.2022.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 02/08/2022] [Accepted: 02/17/2022] [Indexed: 11/24/2022]
Abstract
INTRODUCTION Microultrasound (MicroUS) is a novel imaging modality relying on a high-frequency transducer which confers a three-fold improvement in spatial resolution as compared with conventional transrectal ultrasound. We evaluated the diagnostic value of MRI-MicroUS fusion biopsy and determined the additional benefit of employing MicroUS. METHODS Retrospective analysis of consecutive treatment-naïve men undergoing MRI-MicroUS fusion biopsy between May 2018 and March 2019. Pre-biopsy MRI was systematically reviewed in a dedicated meeting where suspicious lesions PIRADS≥3 were registered and uploaded in the ExactVu MicroUS device. MRI and MicroUS lesions were individually marked in a PIRADS v2 scheme. The biopsy protocol included MRI-MicroUS fusion and MicroUS targeted biopsies; systematic biopsies were performed at clinician's discretion. The diagnostic value was evaluated in terms of detection rate of clinically significant prostate cancer, defined as Gleason pattern≥4 at histology. RESULTS In all, 148 patients with a median age of 69 years (IQR 63-74) and median PSA density of 0.16ng/ml/cc (0.10-0.23) were included. Clinically significant cancer was detected in 42.5% (63/148) patients. MRI detected 89 lesions in the peripheral zone; 73% (65/89) were visible on MicroUS. Clinically significant cancer was detected in 46.1% (30/65) MRI and MicroUS visible lesions, and in 4.2% (1/24) lesions only visible on mpMRI. MicroUS additionally identified 35 suspicious lesions non-visible on MRI of which clinically significant cancer was present in 25.7% (9/35). CONCLUSION Adding MicroUS to the conventional pathway seems to increase the detection rate of clinically significant disease in unselected men undergoing biopsy.
Collapse
Affiliation(s)
- P Martel
- Department of Urology, Lausanne University Hospital, Lausanne, Switzerland
| | - A Rakauskas
- Department of Urology, Lausanne University Hospital, Lausanne, Switzerland
| | - J Dagher
- Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland
| | - S La Rosa
- Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland; Pathology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy
| | - J Y Meuwly
- Department of Radiology, Lausanne University Hospital, Lausanne, Switzerland
| | - B Roth
- Department of Urology, Lausanne University Hospital, Lausanne, Switzerland
| | - M Valerio
- Department of Urology, Lausanne University Hospital, Lausanne, Switzerland.
| |
Collapse
|
23
|
Barletta F, Mazzone E, Gandaglia G, Ploussard G, Rahota RG, Valerio M, Campi R, Mari A, Mattei A, Marra G, Beavaul J, Roumiguié M, Afferi L, Moschini M, Gontero P, Van Der Bergh R, Zhuang J, Hongqian T, Stabile A, Fossati N, De Cobelli F, Esposito A, Brembilla G, Montorsi F, Briganti A. Prostate cancers detected at multi-parametric MRI targeted versus systematic biopsies: are they equal? Results from a large multi-institutional series. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00546-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Gandaglia G, Mazzone E, Ploussard G, Marra G, Valerio M, Campi R, Mari A, Minervini A, Serni S, Moschini M, Marquis A, Beauval JB, Rakauskas A, Sessa F, Van Den Bergh R, Rahota RG, Soeterik T, Roumiguié M, Afferi L, Zhuang J, Guo H, Mattei A, Gontero P, Montorsi F, Briganti A. Definition and predictors of upgrading at final pathology in prostate cancer patients undergoing mri-targeted and systematic biopsies: Results from a large, multi-institutional series. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00700-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Reddy D, Peters M, Shah T, Van Son M, Bertoncelli Tanaka M, Huber P, Lomas D, Rakauskas A, Miah S, Eldred-Evans D, Hosking-Jervis F, Engle R, Dudderidge T, Mccracken S, Greene D, Nigam R, Mccartan N, Valerio M, Orczyk C, Virdi J, Arya M, Ahmed H. Primary focal cryotherapy for non-metastatic prostate cancer: Update from the UK ICE registry. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00406-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Martini A, Wever L, Fankhauser C, Grogg J, Checcucci E, Ploussard G, Affentrager A, Kesch C, Al-Hammouri T, Zattoni F, Marra G, Apfelbeck M, Falagario U, Ettala O, De Angelis M, Briganti A, Jambor I, Kretschmer A, Kasivisvanathan V, Hermans T, Chiu P, Van Den Bergh R, Gandaglia G, Valerio M. Challenging the dogma: Should unilateral pelvic lymph node dissection be envisioned in the multiparametric prostate MRI era? Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00750-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
27
|
Stabile A, Mazzone E, Gandaglia G, Ploussard G, Rahota RG, Valerio M, Campi R, Mari A, Mattei A, Marra G, Beavaul J, Roumiguiè M, Afferi L, Moschini M, Gontero P, Van Den Bergh R, Zhuang J, Tuo H, Fossati N, Montorsi F, Briganti A. The prognostic value of the number of positive targeted cores in men with positive multiparametric magnetic resonance imaging of the prostate. Results from a large, multi-institutional series. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00540-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Gandaglia G, Mazzone E, Stabile A, Barletta F, Bravi C, Cirulli G, Scuderi S, Afferi L, Moschini M, Campi R, Mari A, Rahota R, Ploussard G, Valerio M, Marra G, Marquis A, Beauval J, Roumiguié M, Gontero P, Zhuang J, Tuo H, Fossati N, Montorsi F, Briganti A. Added value of radiological tumor stage in predicting early oncological outcomes in prostate cancer patients undergoing radical prostatectomy within clinical stage: a stage-by-stage analysis. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00972-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
29
|
Mazzone E, Stabile A, Barletta F, Scuderi S, Cirulli G, Robesti D, Ploussard G, Rahota R, Valerio M, Campi R, Mari A, Marra G, Marquis A, Beavaul J, Roumiguié M, Afferi L, Moschini M, Gontero P, Zhuang J, Tuo H, Gandaglia G, Fossati N, Montorsi F, Briganti A. Individualized risk stratification of patients candidate to radical prostatectomy based on clinical and multi-parametric MRI parameters: beyond the conventional clinical risk models. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00967-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
30
|
Cloitre M, Valerio M, Roth B, Berthold D, Tawadros T, Meuwly J, Heym L, Duclos F, Viguet-Carrin S, Vallet V, Bourhis J, Herrera F. PD-0764 Quality of life, toxicity, and PSA control after 50 Gy SBRT to the dominant intraprostatic nodule. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07043-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Gandaglia G, Mazzone E, Barletta F, Cirulli G, Scuderi S, Afferi L, Moschini M, Gacci M, Campi R, Mari A, Berni A, Serni S, Rahota R, Ploussard G, Valerio M, Marra G, Marquis A, Beauval J, Roumiguié M, Gontero P, Zhuang J, Tuo H, Fossati N, Montorsi F, Briganti A. Added value of radiological tumor stage in predicting early oncological outcomes in prostate cancer patients undergoing radical prostatectomy within clinical stage: A stage-by-stage analysis. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01292-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
32
|
Martini A, Soeterik T, Haverdings H, Rahota RG, Checcucci E, De Cillis S, Cirulli G, Hermanns T, Fankhauser C, Afferi L, Mattei A, Kesch C, Heidegger I, Preisser F, Zattoni F, Marquis A, Marra G, Briganti A, Porpiglia F, Van Basten J, Van Den Bergh R, Van Melick H, Ploussard G, Gandaglia G, Valerio M. An algorithm to personalize nerve sparing in men with unilateral high-risk prostate cancer. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01577-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Stabile A, Mazzone E, Barletta F, Sorce G, Pinar U, Seisen T, Roupret M, Ploussard G, De Visschere P, Borgmann E, Heidegger I, Kretschmer A, Surcel C, Tilki D, Tsaur I, Valerio M, Van Der Bergh R, Ost P, Fossati N, Gandaglia G, De Cobelli F, Karakiewicz P, Montorsi F, Briganti A. Development and external validation of a novel tool predicting lymph node invasion in patients with prostate cancer detected at targeted-biopsies. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01583-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
34
|
Gandaglia G, Mazzone E, Stabile A, Scuderi S, Barletta F, Robesti D, Ploussard G, Rahota R, Valerio M, Campi R, Mari A, Marra G, Marquis A, Beavaul J, Roumiguié M, Afferi L, Moschini M, Gontero P, Tuo H, Fossati N, Montorsi F, Briganti A. What is the definition of misclassification in patients with grade group 2 prostate cancer eligible for active surveillance and diagnosed with MRI targeted biopsy? A multi-institutional analysis with pathological confirmation. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01282-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
35
|
Rakauskas A, Peters M, Martel P, La Rosa S, Meuwly JY, Roth B, Valerio M. Tranperineal vs. transrectal micro-ultrasound and mpMRI targeted prostate biopsies: propensity score-matched study. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01324-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
36
|
Reddy D, Peters M, Shah T, Van Son M, Huber P, Lomas D, Rakauskas A, Miah S, Guillaumier S, Dudderidge T, Hindley R, Emara A, Nigam R, Valerio M, Afzal N, Lewi H, Orczyk C, Ogden C, Persad R, Virdi J, Moore C, Arya M, Winkler M, Emberton M, Ahmed H. Cancer control outcomes following focal therapy using HIFU in 1,829 men with non-metastatic prostate cancer treated over 15 years. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01427-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
37
|
Papadimitriou K, Cossu G, Maduri R, Valerio M, Vamadevan S, Daniel RT, Messerer M. Endoscopic treatment of spinal arachnoid cysts. Heliyon 2021; 7:e06736. [PMID: 33889785 PMCID: PMC8050863 DOI: 10.1016/j.heliyon.2021.e06736] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Revised: 02/22/2021] [Accepted: 04/01/2021] [Indexed: 11/18/2022] Open
Abstract
Background/objective Spinal arachnoid cysts (SAC) are intradural lesions, which may provoke a compression of the spinal cord and roots. Endoscopic techniques are increasingly used to minimize the surgical access and the postoperative scar tissue. Shunts may also represent an option. The aim of this paper is to illustrate the technique of endoscopic-assisted fenestration and positioning of a cysto-peritoneal diversion in a thoracic SAC using a flexible endoscope and to perform a systematic literature review on this subject. Material and methods We reported our case and we performed a review of the literature, searching for all the adult cases of Type III SACs in English language treated through endoscopic procedures. Results We found 5 articles matching our search criteria and we included 9 adult patients in our analysis. Six patients were females and the most common localization was the thoracic spine. Six patients underwent selective laminectomies followed by endoscopic fenestration without cyst wall resection. Three patients had a percutaneous endoscopic inspection of the cyst and in two cases a cysto-subarachnoid shunt space was performed. Improvement of pre-operative neurological deficit was reported in six patients, no patients experienced clinical deterioration. The mean follow-up was 22 months and no progression or recurrence was reported. Conclusion The implementation of endoscopy allows a minimally invasive treatments with good visualization of cyst anatomy and precise shunt positioning under real-time guidance. Endoscopy is technically demanding but it can offer similar clinical outcomes when compared to microscopic procedures with a limited rate of post-operative complications. The long-term risk of recurrence should be established by prospective studies.
Collapse
Affiliation(s)
- K Papadimitriou
- Department of Neurosurgery, University Hospital of Lausanne, Lausanne, Switzerland
| | - G Cossu
- Department of Neurosurgery, University Hospital of Lausanne, Lausanne, Switzerland
| | - R Maduri
- Department of Neurosurgery, University Hospital of Lausanne, Lausanne, Switzerland
| | - M Valerio
- Department of Urology, University Hospital of Lausanne, Lausanne, Switzerland
| | - S Vamadevan
- Department of Urology, University Hospital of Lausanne, Lausanne, Switzerland
| | - R T Daniel
- Department of Neurosurgery, University Hospital of Lausanne, Lausanne, Switzerland
| | - M Messerer
- Department of Neurosurgery, University Hospital of Lausanne, Lausanne, Switzerland
| |
Collapse
|
38
|
Patel DA, Salahuddin M, Valerio M, Elerian N, Matthews KJ, McGaha P, Nelson R, Lakey DL. A Participatory, State-Community-Academic Model to Improve Pregnancy Outcomes in Texas: The Healthy Families Initiative. Health Educ Behav 2020; 48:690-699. [PMID: 33307831 DOI: 10.1177/1090198120977156] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND While the Texas infant mortality rate (IMR) is below the Healthy People 2020 objective (5.7 per 1,000 live births), stark differences in IMR are seen across Texas communities. Health indicators for the state suggest important missed opportunities for improving maternal and infant outcomes. The Healthy Families initiative was a collaboration between a Texas state agency, community partners, and academic institutions to understand how evidence-based interventions could be identified, adapted, and implemented to address community priorities and reduce disparities in pregnancy outcomes. METHOD The Healthy Families initiative included two Texas counties, one with low utilization of prenatal care and one with persistent disparities in infant mortality. The model served to (1) identify community factors influencing IMR and maternal morbidity through stakeholder engagement and secondary data, (2) build community capacity to link pregnant women with existing and newly developed services, and (3) develop partnerships within the community and clinics to improve access to and sustainability of services. RESULTS A community-based participatory approach focused on stakeholder engagement was used to identify, design, and adapt strategies to address community-identified priorities. CONCLUSIONS The Healthy Families initiative is a unique state-community-academic partnership aimed at improving pregnancy outcomes in vulnerable communities, with a focus on promotion of capacity building, maintenance, and sustainability of maternal and infant health programs.
Collapse
Affiliation(s)
- Divya A Patel
- The University of Texas Health Science Center at Tyler, Tyler, TX, USA.,Population Health, Office of Health Affairs, The University of Texas System, Austin, TX, USA.,The University of Texas Health Science Center at Houston (UTHealth) School of Public Health in Austin, Austin, TX, USA
| | - Meliha Salahuddin
- The University of Texas Health Science Center at Tyler, Tyler, TX, USA.,Population Health, Office of Health Affairs, The University of Texas System, Austin, TX, USA.,The University of Texas Health Science Center at Houston (UTHealth) School of Public Health in Austin, Austin, TX, USA
| | - Melissa Valerio
- The University of Texas Health Science Center at Houston (UTHealth) School of Public Health in Brownsville, Brownsville, TX, USA
| | - Nagla Elerian
- Population Health, Office of Health Affairs, The University of Texas System, Austin, TX, USA
| | - Krystin J Matthews
- Population Health, Office of Health Affairs, The University of Texas System, Austin, TX, USA.,The University of Texas Health Science Center at Houston (UTHealth) School of Public Health in Austin, Austin, TX, USA
| | - Paul McGaha
- The University of Texas Health Science Center at Tyler, Tyler, TX, USA
| | - Robert Nelson
- The University of Texas Rio Grande Valley, Harlingen, TX, USA
| | - David L Lakey
- Population Health, Office of Health Affairs, The University of Texas System, Austin, TX, USA
| |
Collapse
|
39
|
Surcel C, Mirvald C, Tsaur I, Borgmann H, Heidegger I, Labanaris AP, Sinescu I, Tilki D, Ploussard G, Briganti A, Montorsi F, Mathieu R, Valerio M, Jinga V, Badescu D, Radavoi D, van den Bergh RCN, Gandaglia G, Kretschmer A. Contemporary role of palliative cystoprostatectomy or pelvic exenteration in advanced symptomatic prostate cancer. World J Urol 2020; 39:2483-2490. [PMID: 33135127 DOI: 10.1007/s00345-020-03493-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Accepted: 10/10/2020] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVE To access the feasibility of palliative cystoprostatectomy/pelvic exenteration in patients with bladder/rectal invasion due to prostate cancer (PC). PATIENTS AND METHODS Twenty-five men with cT4 PC were retrospectively identified in the institutional databases of six tertiary referral centers in the last decade. Local invasion was documented by CT or MRI scans and was confirmed by urethrocystoscopy. Oncological therapies, local symptoms, previous local treatments, time from diagnosis to intervention and type of surgical procedure were recorded. Patients were divided into groups: ADT group (12 pts) and 13 pts without any history of previous local/systemic treatments for PCa (nonADT groups). Perioperative complications were classified using the Clavien-Dindo system. Overall survival (OS) was defined as the time from surgery to death from any cause. A Cox regression analysis, stratified for ISUP score and previous hormonal treatment (ADT) was also performed for survival analysis. RESULTS Ileal conduit was the main urinary diversion in both cohorts. For the entire cohort, complication rate was 44%. No significant differences regarding perioperative complications and complication severity between both subgroups were observed (p = 0.2). Median follow-up was 15 months (range 3-41) for the entire cohort with a median survival of 15 months (95% CI 10.1-19.9). In Cox regression analysis stratified for ISUP score, no statistically significant differences in OS in patients with and without previous ADT before cystectomy or exenteration were observed (HR 3.26, 95% CI 0.62-17.23, p = 0.164). CONCLUSION Palliative cystoprostatectomy and pelvic exenteration represent viable treatment options associated with acceptable morbidity and good short-term survival outcome.
Collapse
Affiliation(s)
- C Surcel
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,Department of Urology, Fundeni Clinical Institute, Bucharest, Romania
| | - C Mirvald
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. .,Department of Urology, Fundeni Clinical Institute, Bucharest, Romania.
| | - I Tsaur
- Department of Urology, Johannes Gutenberg University Medical Center, Mainz, Germany
| | - H Borgmann
- Department of Urology, Johannes Gutenberg University Medical Center, Mainz, Germany
| | - Isabel Heidegger
- Department of Urology, Medical University Innsbruck, Innsbruck, Austria
| | - A P Labanaris
- Department of Urology, Interbalkan Medical Center, Thessaloniki, Greece
| | - I Sinescu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,Department of Urology, Fundeni Clinical Institute, Bucharest, Romania
| | - Derya Tilki
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - G Ploussard
- Department of Urology, La Croix du Sud Hospital, Toulouse, France
| | - A Briganti
- Department of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - F Montorsi
- Department of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - R Mathieu
- Department of Urology, CHU Rennes, Rennes, France
| | - M Valerio
- Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - V Jinga
- Urology Department, 'Prof. Dr. Th. Burghele' Clinical Hospital, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
| | - D Badescu
- Urology Department, 'Prof. Dr. Th. Burghele' Clinical Hospital, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
| | - D Radavoi
- Urology Department, 'Prof. Dr. Th. Burghele' Clinical Hospital, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
| | - R C N van den Bergh
- Unit of Urology/Division of Oncology, St Antonius Hospital, Utrecht, Netherlands
| | - G Gandaglia
- Department of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy
| | - A Kretschmer
- Department of Urology, Ludwig-Maximilians University of Munich, Munich, Germany
| | | |
Collapse
|
40
|
Muñoz P, Galar A, Catalán P, Valerio M, Aldamiz-Echevarría T, Cólliga C, Bouza E. The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up. Rev Esp Quimioter 2020; 33:369-378. [PMID: 32729288 PMCID: PMC7528411 DOI: 10.37201/req/072.2020] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Background There are few descriptions of the clinical presentation and evolution of consecutive SARS-CoV-2 infections with a long-enough follow up. Methods Description of the first consecutive 100 patients with microbiologically-proven COVID-19 in a large hospital in Madrid, Spain including a minimum of two-month follow up. Results The median age of the patients (52% males) was 61.5 years (IQR=39.5-82.0) and the median BMI was 28.8 kg/m2 (IQR=24.7-33.7). Overall 72% of the patients had one or more co-morbid conditions with a median age-adjusted Charlson index of 2 (IQR=0-5.7). Five patients (5%) were immunosup-pressed. The most common symptoms at the time of diagnosis were fever (80.0%), cough (53.0%) and dyspnea (23.0%). The median O2 saturation at the time of first examination was 94% (IQR=90-97). Chest X-ray on admission was compatible with pneumonia in 63% of the cases (bilateral in 42% and unilateral in 21%). Overall, 30% were managed at home and 70% were admitted to the hospital. Thirteen patients were admitted to the ICU with a median of 11 days of stay in the Unit (IQR=6.0-28.0). CALL score of our population ranged from 4 to 13. Overall, 60.0% of patients received antibiotic treatment and 66.0%, empirical antiviral treatment, mainly with lopina-vir/ritonavir (65%) or hydroxychloroquine (42%). Mortality, with a minimum of 60 days of follow up, was 23%. The median age of the deceased patients was 85 years (IQR=79-93). Conclusions We found a high mortality in the first 100 patients diagnosed with COVID-19 at our institution, associated with advanced age and the presence of serious underlying diseases.
Collapse
Affiliation(s)
| | - A Galar
- Alicia Galar, Servicio de Microbiología y E. Infecciosas, Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo, 46, 28007 Madrid, Spain.
| | | | | | | | | | | | | |
Collapse
|
41
|
Gandaglia G, Martini A, Ploussard G, Fossati N, Suardi N, Stabile A, Dehò F, Droghetti M, Karakiewicz P, De Visschere P, Borgmann H, Heidegger I, Kretschmer A, Mathieu R, Surcel C, Tilki D, Tsaur I, Valerio M, Van Den Bergh R, Ost P, Montorsi F, Briganti A. External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33703-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
42
|
Gandaglia G, Ploussard G, Valerio M, Mattei A, Marra G, Beauval J, Malavaud B, Roumiguié M, Marquis A, Fossati N, Scalvi F, Robesti D, Rizzo A, Stabile A, Afferi L, Moschini M, Rakauskas A, Van Den Bergh R, De Cobelli F, Fiori C, Porpiglia F, Gontero P, Montorsi F, Briganti A. The added value of concomitant systematic biopsy in predicting biochemical recurrence after radical prostatectomy in patients with prostate cancer diagnosed by MRI-targeted biopsy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33882-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
43
|
Gandaglia G, Ploussard G, Valerio M, Mattei A, Marra G, Beauval JB, Malavaud B, Roumiguié M, Marquis A, Afferi L, Moschini M, Fossati N, Bandini M, Cucchiara V, Stabile A, Bravi C, Rakauskas A, Van Den Bergh R, De Cobelli F, Fiori C, Porpiglia F, Gontero P, Montorsi F, Briganti A. When is mp-MRI reliable in predicting extra-prostatic extension in prostate cancer patients treated with radical prostatectomy? Results from a large, multi-institutional series. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32978-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
44
|
Kadner G, Valerio M, Giannakis I, Arya M, Lumen N, Ho B, Alonso S, Schulman C, Barber N, Amparore D, Porpigila F. Second generation of temporary implantable nitinol device (iTind) in men with lower urinary tract symptoms (LUTS): Who profit most from treatment? 2 year results of the MT-02-study. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32815-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
45
|
Reigadas E, Bouza E, Olmedo M, Vázquez-Cuesta S, Villar-Gómara L, Alcalá L, Marín M, Rodríguez-Fernández S, Valerio M, Muñoz P. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules. J Hosp Infect 2019; 105:319-324. [PMID: 31883938 DOI: 10.1016/j.jhin.2019.12.022] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Accepted: 12/18/2019] [Indexed: 12/17/2022]
Abstract
BACKGROUND Faecal microbiota transplantation (FMT) is a highly effective approach for refractory and recurrent Clostridioides difficile infection (CDI). Despite its excellent efficacy, FMT is not yet a routine procedure in most centres. There is very little experience with FMT based on lyophilized capsules, and data from European institutions are lacking. This article describes our experience with FMT to treat recurrent CDI using lyophilized oral capsules. METHODS A prospectively recorded single-centre case series of patients with recurrent CDI who underwent FMT between January 2018 and May 2019 were analysed. The primary outcome was defined as resolution of CDI without recurrences over a two-month period. Overall resolution was defined as resolution of diarrhoea without recurrence of CDI within two months after a further cycle of FMT. The FMT process involved oral ingestion of four or five lyophilized capsules in a single dose. All stool donors were rigorously screened. FINDINGS FMT was performed in 32 patients. Primary cure was achieved in 81.3% of patients, and the overall cure rate was 87.5%. FMT via lyophilized capsules was well tolerated. No FMT procedure-related adverse events and no further complications were observed for lyophilized-capsule FMT. CONCLUSIONS This initial clinical experience suggests that FMT based on oral lyophilized preparations is a safe, well-tolerated, and highly effective treatment for recurrent CDI. Administration of oral lyophilized capsules seems feasible in hospital routine and will enable FMT to be more widely used.
Collapse
Affiliation(s)
- E Reigadas
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
| | - E Bouza
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain
| | - M Olmedo
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - S Vázquez-Cuesta
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - L Villar-Gómara
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - L Alcalá
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain
| | - M Marín
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain
| | - S Rodríguez-Fernández
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - M Valerio
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain
| | - P Muñoz
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain
| |
Collapse
|
46
|
Martel P, Tawadros T, Burruni R, Rakausakas A, Meuwly J, La Rosa S, Jichlinski P, Valerio M. Utilité de la micro-échographie haute fréquence pour réaliser des biopsies prostatiques ciblées avec fusion d’images performantes. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Cuerpo GP, Valerio M, Pedraz A, Rodríguez-Abella H, Mestres CA, Obrador EQ, González-Calle A, Rodríguez Álvarez R, García PM, Bouza E. Mitral valve repair in infective endocarditis is not inferior to valve replacement: results from a Spanish nationwide prospective registry. Gen Thorac Cardiovasc Surg 2019; 67:585-593. [PMID: 30666586 DOI: 10.1007/s11748-019-01063-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Accepted: 01/07/2019] [Indexed: 02/08/2023]
Abstract
INTRODUCTION Infective endocarditis (IE) still carries high morbidity and mortality and frequently requires surgery. The benefit of mitral valve repair (MVr) in the setting of IE is yet to be proven. The goal of this study was to assess the results of MVr in patients with IE after a minimum follow-up of 1 year. METHODS This study is based on a Spanish nationwide prospective registry that included patients operated on for native mitral valve IE. The collaborating Institutions pooled their pre-, peri-, and postoperative data into the database of the GAMES group [Grupo de Apoyo al Manejo de la EndocarditiS (Group for support and management of infective endocarditis)]. RESULTS Data from 27 hospitals were recorded and 3524 cases of active IE identified between 2008 and 2016. There were 1513 cases of mitral IE, of which 898 involved native valves. Of these, 437 patients underwent surgical treatment, and 369 completed the 1-year follow-up. The valve was repaired in 68 cases (18.4%). Preoperative groups were comparable (EuroSCORE MVr 7.7 vs MVR 8.0; p = ns). Mortality in the repair group was inferior to that in the replacement group (16.2% vs 27.2%, p = 0.058). At 1 year, mortality remained higher in the replacement group: 3.7% vs 2.9%. Relapse of the infection was slightly more frequent in the repair group (7.1% vs 3.7%; p = ns), although this did not lead to higher rates of reintervention (MVr/MVR: 2.9% vs 4.9%). CONCLUSION MVr is an attractive option for specific patients with IE and does not seem to negatively impact on relapses.
Collapse
Affiliation(s)
- Gregorio P Cuerpo
- Servicio de Cirugía Cardíaca, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Department of Cardiac Surgery, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
| | - M Valerio
- Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - A Pedraz
- Servicio de Cirugía Cardíaca, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - H Rodríguez-Abella
- Servicio de Cirugía Cardíaca, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Carlos A Mestres
- Department of Cardiovascular Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | | | - Antonio González-Calle
- Servicio de Cirugía Cardiaca, Unidad del Corazón, Hospital Universitario Virgen del Rocío, Seville, Spain
| | - Regino Rodríguez Álvarez
- Servicio de Microbiología y Enfermedades Infecciosas, Hospital Universitario de Cruces, Bilbao, Spain
| | - Patricia Muñoz García
- Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
- CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain
- Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| | - Emilio Bouza
- Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
- CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain
- Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| | | |
Collapse
|
48
|
Crettenand F, M’Baya O, Jichlinski P, Martel P, Dartiguenave F, Blanc C, Rouvé JD, Valerio M, Cerantola Y, Lucca I. ERAS protocol improves cancer-specific and overall survival after elective radical cystectomy: A retrospective cohort study. Clin Nutr ESPEN 2019. [DOI: 10.1016/j.clnesp.2019.03.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
49
|
La Marca A, Dal Canto M, Buccheri M, Valerio M, Mignini Renzini M, Rodriguez A, Vassena R. A novel transnational fresh oocyte donation (TOD) program based on transport of frozen sperm and embryos. Hum Reprod 2018; 34:285-290. [DOI: 10.1093/humrep/dey331] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2018] [Accepted: 10/19/2018] [Indexed: 11/13/2022] Open
Affiliation(s)
- A La Marca
- Clinica EUGIN, University of Modena and Reggio Emilia, Modena, Italy
| | - M Dal Canto
- Clinica EUGIN, Modena, Italy
- Biogenesi, Reproductive Medicine Centre, Monza, Italy
| | | | | | - M Mignini Renzini
- Clinica EUGIN, Modena, Italy
- Biogenesi, Reproductive Medicine Centre, Monza, Italy
| | | | | |
Collapse
|
50
|
Acosta F, Pérez-Lago L, Ruiz Serrano M, Marín M, Kohl T, Lozano N, Niemann S, Valerio M, Olmedo M, Pérez-Granda M, Pérez Pérez M, Bouza E, Muñoz P, García de Viedma D. Fast update of undetected Mycobacterium chimaera infections to reveal unsuspected cases. J Hosp Infect 2018; 100:451-455. [DOI: 10.1016/j.jhin.2018.08.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 08/28/2018] [Indexed: 10/28/2022]
|